Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 3, 2009, Pages 283-288

  Koutroubakis, Ioannis E ^a   Oustamanolakis, Pantelis ^a   Malliaraki, Niki ^a   Karmiris, Konstantinos ^a   Chalkiadakis, Ioannis ^a   Ganotakis, Emmanouel ^a   Karkavitsas, Nikolaos ^a   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cholesterol; Crohn's disease; Infliximab; Insulin resistance; Ulcerative colitis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESALAZINE; METHOTREXATE; METRONIDAZOLE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CHOLESTEROL; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HUMAN; IN VIVO STUDY; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; FOLLOW UP; INFLAMMATORY BOWEL DISEASES; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN A-I; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62349142022     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328325d42b     Document Type: Article

References (28)

1. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102:174-186.
2. Koutroubakis IE. Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:266-272.
3. Papa A, Santoliquido A, Danese S, Covino M, Di Campli C, Urgesi R, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22:839-846.
4. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:847-855.
5. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109:551-556.
6. Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008; 24:595-603.
7. Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005; 54:789-796.
8. Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenferol Clin Biol 2003; 27:987-991.
9. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudoun T, Kouroumalis EA. Circulating levels of leptin, adiponectin and resistin in inflammatory bowel disease, Inflamm Bowel Dis 2006; 12:100-105.
10. Bregenzer N, Hartmann A, Strauch U, Schölmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease, Inflamm Bowel Dis 2006; 12:53-56.
11. Wassink AM, Olijhoek JK, Visseren FL The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest 2007; 37:8-17.
12. Tesauro M, Schinzari F, Rovella V, Melina D, Mores N, Barini A, et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 2008; 31:1439-1441.
13. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
14. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
15. Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66:958-961.
16. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high-density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33:2440-2446.
17. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26:1495-1498.
18. Gonzalez-Gay MA, De Mafias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, et al. Antitumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:83-86.
19. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64:765-766.
20. Gentile S, Guarino G, Bizzarre A, De Bellis A, Torella R. Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease. Diabetes Obes Metab 2002; 4:276-277.
21. Levy E, Rizwan Y, Thibault L, Lepage G, Brunei S, Bouthillier L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000; 71:807-815.
22. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170 (Suppl):2-6; discussion 16-9.
23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
24. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
25. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. Pediatr Res 2008; 64:673-676.
26. Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, et al. Clinical trial: Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther 2008 [Epub ahead of print]. PMID: 19035968.
27. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxinS (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005; 25:582-591.
28. Koutroubakis IE, Malliaraki N, Vardas E, Ganotakis E, Margioris AN, Manousos ON, et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol 2001; 13:1415-1419.